{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:51:35Z","timestamp":1791341495359,"version":"4.3.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,7,15]],"date-time":"2019-07-15T00:00:00Z","timestamp":1563148800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012319","name":"Max Planck Institute for Dynamics of Complex Technical Systems Magdeburg","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.vaccine.2019.04.030","type":"journal-article","created":{"date-parts":[[2019,4,17]],"date-time":"2019-04-17T11:23:00Z","timestamp":1555500180000},"page":"7019-7028","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1"],"prefix":"10.1016","volume":"37","author":[{"given":"Gwendal","family":"Gr\u00e4nicher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1349-2310","authenticated-orcid":false,"given":"Juliana","family":"Coronel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Pralow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5540-4454","authenticated-orcid":false,"given":"Pavel","family":"Marichal-Gallardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erdmann","family":"Rapp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Karlas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Sandig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2652-5943","authenticated-orcid":false,"given":"Yvonne","family":"Genzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Reichl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.04.030_b0005","first-page":"461","article-title":"Vaccines against influenza WHO position paper","volume":"87","author":"Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.04.030_b0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrd4529","article-title":"Advances in the development of influenza virus vaccines","volume":"14","author":"Krammer","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.vaccine.2019.04.030_b0015","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/nbt1261","article-title":"Vaccine manufacturing: challenges and solutions","volume":"24","author":"Ulmer","year":"2006","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1586\/erv.09.128","article-title":"Continuous cell lines as a production system for influenza vaccines","volume":"8","author":"Genzel","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.04.030_b0025","article-title":"Efforts to Improve the Seasonal Influenza Vaccine","volume":"6","author":"Harding","year":"2018","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.vaccine.2019.04.030_b0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1155\/2015\/504831","article-title":"Current and emerging cell culture manufacturing technologies for influenza vaccines","volume":"2015","author":"Milian","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.vaccine.2019.04.030_b0035","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1016\/j.vaccine.2017.03.102","article-title":"Influenza viruses production: evaluation of a novel avian cell line DuckCelt(R)-T17","volume":"36","author":"Petiot","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0040","doi-asserted-by":"crossref","first-page":"e0141686","DOI":"10.1371\/journal.pone.0141686","article-title":"Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines","volume":"10","author":"Huang","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.030_b0045","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1016\/j.vaccine.2015.06.110","article-title":"Cell substrates for the production of viral vaccines","volume":"33","author":"Aubrit","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0050","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.vaccine.2008.01.032","article-title":"Development and optimisation of a procedure for the production of Parapoxvirus ovis by large-scale microcarrier cell culture in a non-animal, non-human and non-plant-derived medium","volume":"26","author":"Pohlscheidt","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1371\/journal.pone.0182553","article-title":"Efficient and stable production of Modified Vaccinia Ankara virus in two-stage semi-continuous and in continuous stirred tank cultivation systems","volume":"12","author":"Tapia","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2019.04.030_b0060","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1016\/j.vaccine.2014.02.016","article-title":"High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells","volume":"32","author":"Genzel","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0065","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1080\/14789450.2018.1468756","article-title":"Mass spectrometric analysis of glycosylated viral proteins","volume":"15","author":"Harvey","year":"2018","journal-title":"Expert Rev Proteomics"},{"key":"10.1016\/j.vaccine.2019.04.030_b0070","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1016\/j.vaccine.2009.04.076","article-title":"Glycan analysis in cell culture-based influenza vaccine production: Influence of host cell line and virus strain on the glycosylation pattern of viral hemagglutinin","volume":"27","author":"Schwarzer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0075","series-title":"Carbohydrate-Based Vaccines: Methods and Protocols","first-page":"123","article-title":"N-glycosylation fingerprinting of viral glycoproteins by xCGE-LIF","author":"Hennig","year":"2015"},{"key":"10.1016\/j.vaccine.2019.04.030_b0080","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/elps.200800042","article-title":"N-glycan analysis by CGE\u2013LIF: Profiling influenza A virus hemagglutinin N-glycosylation during vaccine production","volume":"29","author":"Schwarzer","year":"2008","journal-title":"Electrophoresis"},{"key":"10.1016\/j.vaccine.2019.04.030_b0085","first-page":"e01693","article-title":"N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for Potency Testing and Immune Processing","volume":"93","author":"Yanming","year":"2019","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0090","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.vaccine.2017.10.112","article-title":"High-cell-density cultivations to increase MVA virus production","volume":"36","author":"Vazquez-Ramirez","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0095","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.biologicals.2007.10.002","article-title":"Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity","volume":"36","author":"Kalbfuss","year":"2008","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.04.030_b0100","series-title":"Animal cell biotechnology: methods and protocols","first-page":"457","article-title":"Vaccine Production","author":"Genzel","year":"2007"},{"key":"10.1016\/j.vaccine.2019.04.030_b0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.chroma.2016.12.076","article-title":"Steric exclusion chromatography for purification of cell culture-derived influenza A virus using regenerated cellulose membranes and polyethylene glycol","volume":"1483","author":"Marichal-Gallardo","year":"2017","journal-title":"J Chromatogr A"},{"key":"10.1016\/j.vaccine.2019.04.030_b0110","doi-asserted-by":"crossref","DOI":"10.1007\/s00253-019-09694-2","article-title":"High titer MVA and influenza A virus production using a hybrid fed-batch\/perfusion strategy with an ATF system","author":"Vazquez-Ramirez","year":"2019","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0115","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1007\/s00253-016-7542-4","article-title":"Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in MDCK cells","volume":"100","author":"Frensing","year":"2016","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0120","doi-asserted-by":"crossref","first-page":"11419","DOI":"10.1038\/s41598-017-11668-1","article-title":"Improvement of the glycoproteomic toolbox with the discovery of a unique C-terminal cleavage specificity of flavastacin for N-glycosylated asparagine","volume":"7","author":"Pralow","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.04.030_b0125","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201800282","article-title":"The fine art of destruction: a guide to in-depth glycoproteomic analyses-exploiting the diagnostic potential of fragment ions","author":"Hoffmann","year":"2018","journal-title":"Proteomics"},{"key":"10.1016\/j.vaccine.2019.04.030_b0130","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nmeth.1322","article-title":"Universal sample preparation method for proteome analysis","volume":"6","author":"Wisniewski","year":"2009","journal-title":"Nat Methods"},{"key":"10.1016\/j.vaccine.2019.04.030_b0135","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1021\/ac1027116","article-title":"Cotton HILIC SPE microtips for microscale purification and enrichment of glycans and glycopeptides","volume":"83","author":"Selman","year":"2011","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2019.04.030_b0140","doi-asserted-by":"crossref","DOI":"10.1021\/acs.analchem.8b02087","article-title":"glyXtoolMS: An open-source pipeline for semiautomated analysis of glycopeptide mass spectrometry data","author":"Pioch","year":"2018","journal-title":"Anal Chem"},{"key":"10.1016\/j.vaccine.2019.04.030_b0145","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1023\/A:1026103405618","article-title":"Equipment design considerations for large scale cell culture","volume":"42","author":"Marks","year":"2003","journal-title":"Cytotechnology"},{"key":"10.1016\/j.vaccine.2019.04.030_b0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cbpa.2007.05.034","article-title":"Bioreactor development for stem cell expansion and controlled differentiation","volume":"11","author":"King","year":"2007","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0155","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2010.07.004","article-title":"A new MDCK suspension line cultivated in a fully defined medium in stirred-tank and wave bioreactor","volume":"28","author":"Lohr","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0160","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1472-6750-11-84","article-title":"Metabolic and Kinetic analyses of influenza production in perfusion HEK293 cell culture","volume":"11","author":"Petiot","year":"2011","journal-title":"BMC Biotech"},{"key":"10.1016\/j.vaccine.2019.04.030_b0165","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/BF02922022","article-title":"Growth inhibition in animal cell culture. The effect of lactate and ammonia","volume":"30","author":"Hassel","year":"1991","journal-title":"Appl Biochem Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0170","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/bit.260390408","article-title":"Effects of ammonia and lactate on hybridoma growth, metabolism, and antibody production","volume":"39","author":"Ozturk","year":"1992","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.04.030_b0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0141-0229(00)00151-4","article-title":"Effects of ammonia and lactate on growth, metabolism, and productivity of BHK cells","volume":"27","author":"Cruz","year":"2000","journal-title":"Enzyme Microb Technol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0168-1656(95)00196-4","article-title":"The importance of ammonia in mammalian cell culture","volume":"46","author":"Schneider","year":"1996","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0185","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1472-6750-14-72","article-title":"The avian cell line AGE1.CR.pIX characterized by metabolic flux analysis","volume":"14","author":"Lohr","year":"2014","journal-title":"BMC Biotech"},{"key":"10.1016\/j.vaccine.2019.04.030_b0190","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00253-010-2742-9","article-title":"MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation","volume":"88","author":"Genzel","year":"2010","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0195","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1016\/j.vaccine.2010.03.029","article-title":"Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturing","volume":"28","author":"Le Ru","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0200","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s00253-012-4238-2","article-title":"CAP, a new human suspension cell line for influenza virus production","volume":"97","author":"Genzel","year":"2013","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0205","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1126\/science.130.3373.432","article-title":"Amino acid metabolism in mammalian cell cultures","volume":"130","author":"Eagle","year":"1959","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2019.04.030_b0210","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jbiotec.2005.03.009","article-title":"Effect of re-feed strategies and non-ammoniagenic medium on adenovirus production at high cell densities","volume":"119","author":"Ferreira","year":"2005","journal-title":"J Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0215","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/bit.260390605","article-title":"Quantification of cell culture factors affecting recombinant protein yields in baculovirus-infected insect cells","volume":"39","author":"Lindsay","year":"1992","journal-title":"Biotechnol Bioeng"},{"key":"10.1016\/j.vaccine.2019.04.030_b0220","doi-asserted-by":"crossref","first-page":"7091","DOI":"10.1016\/j.vaccine.2014.10.067","article-title":"Rational design of medium supplementation strategy for improved influenza viruses production based on analyzing nutritional requirements of MDCK Cells","volume":"32","author":"Huang","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0225","series-title":"Cell Culture Engineering","first-page":"75","article-title":"The \u201cPush-to-Low\u201d Approach for Optimization of High-Density Perfusion Cultures of Animal Cells","author":"Konstantinov","year":"2006"},{"key":"10.1016\/j.vaccine.2019.04.030_b0230","doi-asserted-by":"crossref","DOI":"10.1007\/s00253-018-9275-z","article-title":"Process intensification of EB66(R) cell cultivations leads to high-yield yellow fever and Zika virus production","author":"Nikolay","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0235","unstructured":"EMA \u2013 Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products - draft (2009); 2013."},{"key":"10.1016\/j.vaccine.2019.04.030_b0240","unstructured":"EMA \u2013 Guideline on Influenza Vaccines - Quality module (2017); 2017."},{"key":"10.1016\/j.vaccine.2019.04.030_b0245","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4049\/jimmunol.1201060","article-title":"Toward animal cell culture-based influenza vaccine design: viral hemagglutinin N-glycosylation markedly impacts immunogenicity","volume":"190","author":"Hutter","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0250","first-page":"01084","article-title":"Glycan-dependent immunogenicity of recombinant soluble trimeric hemagglutinin","volume":"JVI","author":"de Vries","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2019.04.030_b0255","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3390\/v6031294","article-title":"Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection","volume":"6","author":"Tate","year":"2014","journal-title":"Viruses."},{"key":"10.1016\/j.vaccine.2019.04.030_b0260","series-title":"Vaccine development and manufacturing","first-page":"97","article-title":"Viral vaccines purification","author":"Kalbfuss","year":"2014"},{"key":"10.1016\/j.vaccine.2019.04.030_b0265","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/elsc.201700108","article-title":"Optimization of cell culture-derived influenza A virus particles purification using sulfated cellulose membrane adsorbers","volume":"18","author":"Fortuna","year":"2018","journal-title":"Eng Life Sci"},{"key":"10.1016\/j.vaccine.2019.04.030_b0270","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.vaccine.2013.11.044","article-title":"Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor","volume":"32","author":"Tapia","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.04.030_b0275","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1016\/S0264-410X(00)00508-9","article-title":"The human cell line PER.C6 provides a new manufacturing system for the production of influenza vaccines","volume":"19","author":"Pau","year":"2001","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19304815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:37:15Z","timestamp":1759401435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19304815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":55,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["S0264410X19304815"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.04.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}